Conference on Outsourcing Protein Therapeutics: Solution to Capacity Demand
October 15 - 16, 2001
srinstitute.com
Three sessions at the end deal with producing proteins in plants:
1:35 - 2:25 - Platibodies Production: Feasibility Through Large-Scale Commercial Supply
Monoclonal antibodies are the fastes-growing class of novel therapeutic approaches to disease management in both the developmental and commercial pharmaceutical marketplaces. This extraordinary growth has caused severe capacity shortfall in the production of antibodies by standard CHO cell culture manufacturing. Epicyte's proprietary Plantibody technology provieds high-quality, cost-advantaged human monoclonal antibodies at large scale. Scaling of these biopharmaceuticals to metric ton levels can be achieved very rapidly. We will descibe the Epicyte-Dow partnership which will supply anitbodies from preclinical testing to commercial production and discuss how Product Stewardship is an essential compnent in assuring product purity and minimizing environment impact.
Speaker
Vincent Gotz
Vice President, Business Development
Epicyte Pharmaceutical, Inc
Kerr Anderson, Ph.D.
Technical Director and Scientist
The Dow Chemical Company
2:25 - 3:00 - From the field to the Clinic: Large Scale Production of recombinant Proteins in Corn Seeds
Meristem Therapeutics has developed industrial processes for the large scale, cost effective produciotn of remobinant therapeutic proteins in genitically enginnered transgenic plants. Different plant species, such as tabacco cron, or micro-algae are used as bioreactors for the production of recombinant enzymes, antibodies, vaccines or other substitutive proteins of therapeutic interest. Expressionm cassettes are thereby carefully adapted to obtain high level expression of correctly processed functional protein in a given host plant organ. Extraction and purification processes are developed in our industrial pilot plant to produce large quantities of recombinant proteins from field grown transgenic plants or from plant biomass obatained by fermentation. New rapid production methods for recombinant proteins at the mg to gram level have recently been developed, that allow the efficeitn screening of proteins as potential drug candidates for pharmaceutical applications. As an illustration data will be presented for the production of several recombinant proteins such as human lactoferrin, human collagen and gastric lipase for the treatment of exocrine pancreatic insufficiencies.
Speaker
Manfred Theisen, Ph.D.
VP, Business Development
Meristem Therapeutics, France
3:00 - 3:35 - Using Transgenic Plants as "Biorectors" to Produce Therapeutic Proteins
The potential of "molecular pharming", using transgenic plants as "bioreactors" to produce therapeutic proteins, ahs been apparent for over a decade and several proteins produced in these systems are now in clinical trials. Plants can assemble the novel muscosal antibody, secretory IgA which is comprised of 4 polypeptide chains. this opens up numerous novel therapeutic uses particularly in mucosal medicine. Clinical trials for prevention of dental caries will be discussed. Based the initial success of this plantibody, the future will wintess a plethora of antibody products produced using plant bioreactors.
Speaker
James W. Larrick, M.D., Ph.D.
President & CEO
The web page doesn't list the company of Dr Larrick, but the brochure I have says "Planet Biotechnology".
Jason |
